XAGE-1 mRNA expression in prostate cancer and antibody response in patients

Microbiology and Immunology

Volumn 49, Issue 5, 2005, Pages 471-476

  Koizumi, Fumihito ^a   Noguchi, Yuji ^a   Saika, Takashi ^a   Nakagawa, Kazuhiko ^a   Sato, Shuichiro ^a   Eldib, Ali Mohamed Ali ^a   Nasu, Yasutomo ^a   Kumon, Hiromi ^a   Nakayama, Eiichi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Cancer testis antigen; Prostate cancer; XAGE 1

Indexed keywords

CANCER VACCINE; MESSENGER RNA; PROTEIN ANTIBODY; RECOMBINANT PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR XAGE 1A; TRANSCRIPTION FACTOR XAGE 1B; TRANSCRIPTION FACTOR XAGE 1C; TRANSCRIPTION FACTOR XAGE 1D; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; BLOOD ANALYSIS; CANCER LOCALIZATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 20444366620     PISSN: 03855600     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2005.tb03751.x     Document Type: Article

References (23)

1. Ali Eldib, A.M., Ono, T., Shimono, M., Kanako, M., Tanaka, R., Noguchi, Y., and Nakayama, E. 2004. Immuno-screening of a cDNA library from a lung cancer cell line using autologous patient serum: identification of XAGE-1b as a dominant antigen and its immunogenicity in lung adenocarcinoma. Int. J. Cancer 108: 558-563.
2. Atanackovic, D., Altorki, N.K., Stockert, E., Williamson, B., Jungbluth, A.A., Ritter, E., Santiago, D., Ferrara, C.A., Matsuo, M., Selvakumar, A., Dupont, B., Chen, Y.T., Hoffman, E.W., Ritter, G., Old, L.J., and Gnjatic, S. 2004. Vaccine-induced CD44- T cell responses to MAGE-3 protein in lung cancer patients. J. Immunol. 172: 3289-3296.
3. Ayyoub, M., Stevanovic, S., Sahin, U., Guillaume, P., Servis, C., Rimoldi, D., Valmori, D., Romero, P., Cerottini, J.C., Rammensee, H.G., Pfreundschuh, M., Speiser, D., and Levy, F. 2002. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. J. Immunol. 168: 1717-1722.
4. Boon, T., and Old, L.J. 1997 Cancer tumor antigens. Curr. Opin. Immunol. 9: 681-683.
5. Brinkmann, U., Vasmatzis, G., Lee, B., and Pastan, I. 1999. Novel genes in the PAGE and GAGE family of tumor antigens found by homology walking in the dbEST database. Cancer Res. 59: 1445-1448.
6. Davis, I.D., Chen, W., Jackson, H., Parente, P., Shackleton, M., Hopkins, W., Chen, Q., Dimopoulos, N., Luke, T., Murphy, R., Scott, A.M., Maraskovsky, E., McArthur, G., MacGregor, D., Sturrock, S., Tai, T.Y., Green, S., Cuthbertson, A., Maher, D., Miloradovic, L., Mitchell, S.V., Ritter, G., Jungbluth, A.A., Chen, Y.T., Gnjatic, S., Hoffman, E.W., Old, L.J., and Cebon, J.S. 2004. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc. Natl. Acad. Sci. U.S.A. 101: 10697-10702.
7. Egland, K.A., Kumar, V., Duray, P., and Pastan, I. 2002. Characterization of overlapping XAGE-1 transcripts encoding a cancer testis antigen expressed in lung, breast, and other types of cancers. Mol. Cancer Ther. 7: 441-450.
8. Fossa, A., Alsoe, L., Crameri, R., Funderud, S., Gaudernack, G., and Smeland, E.B. 2004. Serological cloning of cancer/testis antigens expressed in prostate cancer using cDNA phage surface display. Cancer Immunol. Immunother. 53: 431-438.
9. Gleason, D.F. 1966. Classification of prostatic carcinomas. Cancer Chemother. Rep. 50: 125-128.
10. Howe, H.L., Wingo, P.A., Thun, M.J., Ries, L.A., Rosenberg, H.M., Feigal, E.G., and Edwards, B.K. 2001. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J. Natl. Cancer Inst. 93: 824-842.
11. Jäger, E., Chen, Y.T., Drijfhout, J.W., Karbach, J., Ringhoffer, M., Jager, D., Arand, M., Wada, H., Noguchi, Y., Stockert, E., Old, L.J., and Knuth, A. 1998. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 187: 265-270.
12. Jäger, E., Gnjatic, S., Nagata, Y., Stockert, E., Jager, D., Karbach, J., Neumann, A., Rieckenberg, J., Chen, Y.T., Ritter, G., Hoffman, E., Arand, M., Old, L.J., and Knuth, A. 2000. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc. Natl. Acad. Sci. U.S.A. 97: 12198-12203.
13. Kitagawa, T., Tsukuma, H., and Tominaga, S. 1999. Prediction of cancer incidence in Japan. Cancer Statics-1999, Shinohara Shuppan, Tokyo, p. 28.
14. Kurashige, T., Noguchi, Y., Saika, T., Ono, T., Nagata, Y., Jungbluth, A., Ritter, G., Chen, Y.T., Stockert, E., Tsushima, T., Kumon, H., Old, L.J., and Nakayama, E. 2001. NY-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. Cancer Res. 61: 4671-4674.
15. Liu, X.F., Helman, L.J., Yeung, C., Bera, T.K., Lee, B., and Pastan, I. 2000. XAGE-1, a new gene that is frequently expressed in Ewing's sarcoma. Cancer Res. 60: 4752-4755.
16. Loblaw, D.A., Mendelson, D.S., Talcott, J.A., Virgo, K.S., Somerfield M.R., Ben-Josef, E., Middleton, R., Porterfield, H., Sharp, S.A., Smith, T.J., Taplin, M.E., Vogelzang, N.J., Wade, J.L., Jr., Bennett, C.L., and Scher, H.I. 2004. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J. Clin. Oncol. 22:2927-2941.
17. Lonchay, C., Van Der Bruggen, P., Connerotte, T., Hanagiri, T., Coulie, P., Colau, D., Lucas, S., Van Pel, A., Thielemans, K., Van Baren, N., and Boon, T. 2004. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc. Natl. Acad. Sci. U.S.A. 101: 14631-14638.
18. Nakada, T., Noguchi, Y., Satoh, S., Ono, T., Saika, T., Kurashige, T., Gnjatic, S., Ritter, G., Chen, Y.T., Stockert, E., Nasu, Y., Tsushima, T., Kumon, H., Old, L.J., and Nakayama, E. 2003. NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. Cancer Immun. 3: 10.
19. Patard, J.J., Brasseur, F., Gil-Diez, S. Radvanyi, F., Marchand, M., Francois, P., Abi-Aad, A., Van Cangh, P., Abbou, C.C., and Chopin, D. 1995. Expression of MAGE genes in transitional-cell carcinomas of the urinary bladder. Int. J. Cancer 64: 60-64.
20. Scanlan, M.J., Güre, A.O., Jungbluth, A.A., Old, L.J., and Chen, Y.T. 2002. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev. 188: 22-32.
21. Smith, D.C. 1999. Chemotherapy for hormone refractory prostate cancer. Urol. Clin. North Am. 26: 323-331.
22. Zendman, A.J., Van Kraats, A.A., Den Hollander, A.I., Weidle, U.H., Ruiter, D.J., and Van Muijen, G.N. 2002. Characterization of XAGE-1b, a short major transcript of cancer/testis-associated gene XAGE-1, induced in melanoma metastasis. Int. J. Cancer 97: 195-204.
23. Zendman, A.J., Van Kraats, A.A., Weidle, U.K., Ruiter, D.J., and Van Muijen, G.N. 2002. The XAGE family of cancer/testis-associated genes: alignment and expression profile in normal tissues, melanoma lesions and Ewing's sarcoma. Int. J. Cancer 99: 361-369.